The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. CTAF convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care.
CTAF directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes.
All members of the CTAF Panel must meet ICER’s criteria for Conflict of Interest.
For an archive of CTAF reports published prior to September 2013, please visit this page.
The California Technology Assessment Forum will convene to discuss ICER's report on treatments for Multiple Sclerosis. More information, including key dates for the report, will be available in the coming weeks.
Diabetes Prevention Programs
The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus each year. The direct medical costs of diabetes were estimated to be $176 billion in 2012. Interventions to prevent diabetes have the potential to save the health care system substantial medical costs by reducing the incidence of diabetes and its associated complications. The Diabetes Prevention Program Trial (DPPT) demonstrated that the incidence of diabetes could be reduced using intensive diet and lifestyle counseling for individuals at very high risk for diabetes. Since publication of the trial results, many commercial programs have been developed to implement a scalable version of the DPPT intervention using fewer resources.
Intervention of interest: Diabetes prevention programs
Date of review: June 2016View materials